• Explore /
  • Poster
  • / Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Neurologic assessment in neuro-oncology (NANO) scale in a prospective phase II trial of anti-PD1 antibody, pembrolizumab with or without bevacizumab in patients with recurrent glioblastoma.

Abstract Poster

Authors

null

Lakshmi Nayak

Dana-Farber Cancer Institute, Boston, MA

Lakshmi Nayak , Timothy Smith , Sarah C. Gaffey , Katherine B. Peters , Jennifer Leigh Clarke , Justin T Jordan , John Frederick De Groot , Phioanh Leia Nghiemphu , Thomas Joseph Kaley , Howard Colman , Terri Armstrong , Martin J. Taphoorn , Victoria Caruso , Myriam Bednarek Debruyne , Chinmay Bhavsar , Annette M Molinaro , Mariano Severgnini , Patrick Y. Wen , David A. Reardon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT02337491

Citation

J Clin Oncol 36, 2018 (suppl; abstr 2037)

DOI

10.1200/JCO.2018.36.15_suppl.2037

Abstract #

2037

Poster Bd #

195

Abstract Disclosures

Similar Posters

First Author: Jian Li Campian

First Author: Yoo Na Kim

First Author: Mason Webb

First Author: John Yohan Rhee